Intec Parent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Q BioMed (OTCMKTS:QBIO – Get Rating) and Indaptus Therapeutics (NASDAQ:INDP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Profitability This table compares Q BioMed and Indaptus Therapeutics’ […]

Intec Closes Merger with Decoy Biosystems USA - English Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus News provided by Share this article Share this article NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus T...

Health your username 6 days ago A stockholder is suing Intec Pharma Ltd., Intec’s board of directors, and related entities over alleged violations of the Securities Exchange Act, per a Friday complaint filed in the District of Delaware regarding a proposed merger. Plaintiff Craig Davidson is an owner of common stock of Intec, a biopharmaceutical company developing drug products based on its Accordion Pill platform that seeks to “improve the efficacy and safety” of drug products. On March 15, Intec’s board of directors executed a merger agreement with Intec Parent, Inc., Dillion Merge...